Of note, treatment with an ABCA1 agonist increased gene expression of enzymes involved in cholesterol biosynthesis in ASTRs, and improved clinical outcome in experimental autoimmune encephalomyelitis (Itoh et al., 2018). Here, ABCA1 is linked to experimental autoimmune encephalomyelitis.